Skip to main content
Clinical Trials/NCT05066711
NCT05066711Enrolling By InvitationNot Applicable

A Prospective, Multicenter Study Evaluating the Safety and Performance of the NuVasive® ACP System for the Treatment of Patients With Pathologic Conditions of the Cervical Spine

NuVasive3 sites in 1 country75 target enrollmentStarted: May 22, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Enrolling By Invitation
Sponsor
Enrollment
75
Locations
3
Primary Endpoint
Complications NuVasive ACP System

Study Overview

Brief Summary

The primary objective of this study is to evaluate the safety and performance of anterior cervical spine surgery using the NuVasive anterior cervical plate (ACP) System as measured by reported complications, radiographic outcomes, and patient-reported outcomes (PROs).

Detailed Description

This study is a prospective, uncontrolled, multicenter study to evaluate the safety and performance of the NuVasive ACP System in patients who undergo anterior cervical spine surgery. Consecutive patients at a given site who meet eligibility requirements will be asked to consent to participate in the study. These patients will present with pathologic conditions in the cervical spine that are amenable to surgical treatment and will be screened prior to study enrollment. Once enrolled in the study, subjects will undergo anterior cervical spine surgery using the NuVasive ACP System based on the surgeon's standard of care. At least 75 subjects will be enrolled and will be followed for 24 months after the surgery.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients who are ≥18 years of age at the time of consent
  • Have planned anterior cervical (C2 to C7) spine surgery using the NuVasive ACP System in conjunction with a NuVasive interbody implant or vertebral body replacement device (VBR), or a structural bone allograft spacer, for treatment of any of the following conditions:
  • degenerative disc disease, as defined by neck pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies
  • trauma (including fractures)
  • tumors involving the cervical spine
  • cervical spinal deformity (kyphosis, lordosis, or scoliosis)
  • failed previous cervical fusion(s) (e.g., pseudoarthrosis)
  • cervical spondylolisthesis
  • cervical spinal stenosis
  • Able to undergo surgery based on physical exam, medical history, and surgeon judgment
  • Understands the conditions of enrollment and is willing to sign an informed consent form to participate in the study

Exclusion Criteria

  • Procedures performed with interbody implants with integrated vertebral body screw(s)
  • Patient is involved in active litigation relating to the spine (worker's compensation claim is allowed if it is not contested)
  • Use of bone growth stimulators postoperatively
  • Active smoking within 6 weeks of surgery
  • Patient has known sensitivity to materials implanted
  • Systemic or local infection (latent or active) or signs of local inflammation
  • Patient has inadequate bone stock or quality, or a physical or medical condition that would prohibit beneficial surgical outcome based on surgeon judgment
  • Pregnant, or plans to become pregnant
  • Patient is a prisoner
  • Patient is participating in another clinical study that would confound study data

Outcomes

Primary Outcomes

Complications NuVasive ACP System

Time Frame: 24 months

Rate of complications (i.e., safety) attributable to use of the NuVasive ACP System

Radiographic Success

Time Frame: 24 months

Proportion of subjects with radiographic success at: 1. Latest time point available for patients undergoing surgery to treat advanced stage tumors 2. 24 months postoperative for subjects undergoing surgery to treat instabilities, traumatic spinal fractures, failed previous fusions, or degenerative disease

Secondary Outcomes

  • Rate of complications attributable to the use of NuVasive instruments, implants, or technologies(24 months)
  • Clinical Outcome Success(24 months)
  • Rate of Postoperative Dysphagia(24 months)

Investigators

Sponsor
NuVasive
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials

NuVasive® ACP System Study | Clinical Trial